Advanced

The effect of vitamin B-12 on total plasma homocysteine concentration in folate-replete hemodialysis patients

Arnadottir, M and Hultberg, Björn LU (2003) In Clinical Nephrology 59(3). p.186-189
Abstract
Aim: Results from several studies indicate that the total homocysteine (tHcy) concentration in plasma is an independent risk factor for cardiovascular disease in hemodialysis patients. Folic acid is the established mainstay of homocysteine-lowering treatment, but since such treatment does not normalize plasma tHcy concentration in hemodialysis patients, it is of importance to search for additional therapy. Methods: Twenty-eight folate-replete hemodialysis patients were randomized to 2 equally sized groups, a treatment group and a control group. The treatment group received vitamin B 12 tablets at a dose of 2 mg 3 times a week for 6 weeks (after each dialysis session) while the control group received no such treatment. Blood samples were... (More)
Aim: Results from several studies indicate that the total homocysteine (tHcy) concentration in plasma is an independent risk factor for cardiovascular disease in hemodialysis patients. Folic acid is the established mainstay of homocysteine-lowering treatment, but since such treatment does not normalize plasma tHcy concentration in hemodialysis patients, it is of importance to search for additional therapy. Methods: Twenty-eight folate-replete hemodialysis patients were randomized to 2 equally sized groups, a treatment group and a control group. The treatment group received vitamin B 12 tablets at a dose of 2 mg 3 times a week for 6 weeks (after each dialysis session) while the control group received no such treatment. Blood samples were collected before and at the end of the treatment period for analysis of tHcy in plasma and vitamin B-12, methylmalonic acid as well as folate in serum. Results: At the end of the study period, serum vitamin B12 concentrations were significantly higher in the treatment group than in the control group. Plasma tHcy concentrations decreased significantly in both groups during the study period. However, there was no difference between the responses of the 2 groups. Conclusion: The results of this open, randomized controlled study did not support the hypothesis that treatment with oral vitamin B12 has considerable homocysteine-lowering effect in folate-replete hemodialysis patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
vitamin B-12, homocysteine, dialysis, folic acid
in
Clinical Nephrology
volume
59
issue
3
pages
186 - 189
publisher
Dustri-Verlag
external identifiers
  • wos:000181185200006
  • pmid:12653261
  • scopus:0037345459
ISSN
0301-0430
language
English
LU publication?
yes
id
b9b79124-24a1-490b-9083-487e68755353 (old id 317923)
alternative location
http://www.clinnephrol.com/index.php?id=10&issueId=17
date added to LUP
2007-08-22 13:09:25
date last changed
2018-01-07 09:00:44
@article{b9b79124-24a1-490b-9083-487e68755353,
  abstract     = {Aim: Results from several studies indicate that the total homocysteine (tHcy) concentration in plasma is an independent risk factor for cardiovascular disease in hemodialysis patients. Folic acid is the established mainstay of homocysteine-lowering treatment, but since such treatment does not normalize plasma tHcy concentration in hemodialysis patients, it is of importance to search for additional therapy. Methods: Twenty-eight folate-replete hemodialysis patients were randomized to 2 equally sized groups, a treatment group and a control group. The treatment group received vitamin B 12 tablets at a dose of 2 mg 3 times a week for 6 weeks (after each dialysis session) while the control group received no such treatment. Blood samples were collected before and at the end of the treatment period for analysis of tHcy in plasma and vitamin B-12, methylmalonic acid as well as folate in serum. Results: At the end of the study period, serum vitamin B12 concentrations were significantly higher in the treatment group than in the control group. Plasma tHcy concentrations decreased significantly in both groups during the study period. However, there was no difference between the responses of the 2 groups. Conclusion: The results of this open, randomized controlled study did not support the hypothesis that treatment with oral vitamin B12 has considerable homocysteine-lowering effect in folate-replete hemodialysis patients.},
  author       = {Arnadottir, M and Hultberg, Björn},
  issn         = {0301-0430},
  keyword      = {vitamin B-12,homocysteine,dialysis,folic acid},
  language     = {eng},
  number       = {3},
  pages        = {186--189},
  publisher    = {Dustri-Verlag},
  series       = {Clinical Nephrology},
  title        = {The effect of vitamin B-12 on total plasma homocysteine concentration in folate-replete hemodialysis patients},
  volume       = {59},
  year         = {2003},
}